Ambry Genetics Launches Comprehensive Multi-Gene Test for Hereditary Prostate Cancer


Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Offers Solution to Recent Research Showing Higher Rate of Germline Mutations
in Men with Metastatic Prostate Cancer

Aliso Viejo, CA – September 28, 2016 – Ambry Genetics (Ambry) today announces that it has launched ProstateNext, a new 14-gene panel for hereditary prostate cancer. Ambry will feature it at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference taking place September 28-October 1 in Seattle, WA. This also coincides with Prostate Cancer Awareness Month and follows a recent New England Journal of Medicine (NEJM) article demonstrating a higher frequency of germline mutations in men with metastatic prostate cancer.

Prostate cancer is the second most common cancer among men in the U.S.1, representing 10.7% of all new cancer cases in the country.2 The median age at diagnosis for these men is 66 years.2

Due to available screening and treatment, prostate cancer in general has excellent survival rates, but death rates are higher in certain men, including those with advanced stage cancer (such as metastatic cancer).2

Several factors place a man at increased risk for prostate cancer, and these can include family history and germline mutations. Hereditary prostate cancer, the type caused by germline mutations traveling through a family, is believed to account for 5-10% of all prostate cancer (although this estimate is being refined with ongoing research). A germline mutation found in a man with prostate cancer can open the door to individualized prostate cancer treatment and/or screening for it and related cancers. 

Michelle Jackson, MS, CGC, Ambry Genetic Counselor and Oncology Product Manager, said, “Germline genetic testing can help a man that has had prostate cancer learn about his risk for other cancers, and determine if his family members may also be at increased risk. Existing medical management guidelines recommending additional cancer screening can empower these families to be proactive about their health, particularly once genetic testing confirms the risk.”

Common causes of hereditary prostate cancer are germline BRCA1 or BRCA2 gene mutations, which can often be associated with a more aggressive form of prostate cancer. Mutations in other genes also contribute to hereditary prostate cancer including ATM, CHEK2, genes associated with Lynch syndrome (MLH1, MSH2, MSH6, PMS2) and several others; these may also convey risks to other cancers, like pancreatic, breast, and colorectal cancer.

ProstateNext includes germline evaluation (next generation sequencing (NGS) and deletion/duplication analysis) of 14 genes: ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, and TP53. Ambry’s team selected these genes using scientific evidence confirming an association with prostate cancer; the same genes encompass risks for male breast cancer, colorectal cancer and more.

Jackson offered, “At Ambry we thoughtfully create and launch our testing, often fulfilling a deeper professional or personal meaning. Not only does offering ProstateNext at this time allow Ambry to bring much-needed attention to prostate cancer, one of the most common cancers diagnosed in men, but we are able to do so during a very meaningful time – Prostate Cancer Awareness Month.” 

The new testing option also offers a solution to a peer-reviewed international study recently published in NEJM. This identified an 11.8% germline mutation rate in men with metastatic prostate cancer, higher than that found in men with localized prostate cancer (n=692), and a potential need for germline testing to find DNA-repair gene mutations in these men. All genes included in ProstateNext are mentioned in the study. 

Ambry is pleased to share details about ProstateNext with genetic counselors and other clinicians caring for families affected by hereditary prostate cancer at the NSGC conference this week.

For more details about Ambry’s hereditary cancer genetic testing, please visit here

About Ambry Genetics ®

Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer the most comprehensive genetic testing menu in the industry. Ambry is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. As part of the Konica Minolta family, Ambry is responsibly applying new technologies to the clinical molecular diagnostics market to bring about precision medicine. For more information about Ambry Genetics, visit

Press Contact:
Dina Scaglione
Director, Marketing
949 457 4355

Search Results

Start your search...